Oncology is trailblazing the field of engineered cellular therapeutics. This Review discusses the goals of cellular immunotherapy in cancer, key challenges facing the field and strategies to overcome them-paving the way for treatment of other diseases.This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-modified T cells for refractory leukemia. The widespread commercial approval of genetically engineered T cells for a variety of blood cancers offers hope for patients with other types of cancer, and the convergence of human genome engineering and cell therapy technology holds great potential for generation of a new class of cellular therapeutics. In this Review, we discuss the goals of cellular immunotherapy in cancer, key challenges facing the field and exciting strategies that are emerging to overcome these obstacles. Finally, we outline how developments in the cancer field are paving the way for cellular immunotherapeutics in other diseases.
Engineered cellular immunotherapies in cancer and beyond / Finck, A. V.; Blanchard, T.; Roselle, C. P.; Golinelli, G.; June, C. H.. - In: NATURE MEDICINE. - ISSN 1078-8956. - 28:4(2022), pp. 678-689. [10.1038/s41591-022-01765-8]
Engineered cellular immunotherapies in cancer and beyond
Golinelli G.;
2022
Abstract
Oncology is trailblazing the field of engineered cellular therapeutics. This Review discusses the goals of cellular immunotherapy in cancer, key challenges facing the field and strategies to overcome them-paving the way for treatment of other diseases.This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-modified T cells for refractory leukemia. The widespread commercial approval of genetically engineered T cells for a variety of blood cancers offers hope for patients with other types of cancer, and the convergence of human genome engineering and cell therapy technology holds great potential for generation of a new class of cellular therapeutics. In this Review, we discuss the goals of cellular immunotherapy in cancer, key challenges facing the field and exciting strategies that are emerging to overcome these obstacles. Finally, we outline how developments in the cancer field are paving the way for cellular immunotherapeutics in other diseases.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
